Overall survival analysis of a heavily pretreated population of patients with bone sarcomas treated with mecbotamab vedotin, a conditionally binding ADC targeting AXL.

Journal of Clinical Oncology 2026

View at publisher
Authors: Anthony Paul Conley, Seth M. Pollack, Mihaela Druta, William D. Tap, Chueh-Chuan Yen, John A. Charlson, Lara E. Davis, Anna Weinberg Chalmers, Elizabeth T. Loggers, Jaspreet Singh Grewal, Gerald Steven Falchook, Brian C. Schulte
+8 more Thomas Yau, AeRang Kim, Herbert Ho-Fung Loong, Suzanne George, Bhuvana A. Setty, Leo Mascarenhas, Gregory Michael Cote, Breelyn A. Wilky
DOI: 10.1200/jco.2026.44.16_suppl.11511
Cited by: 1

Abstract

11511 Background: Patients with metastatic bone sarcomas continue to lack effective therapies. AXL, a cell-surface receptor tyrosine kinase, is highly expressed in bone sarcoma subtypes and has been shown to drive increased metastasis, resistance to chemotherapy, and poor outcomes. Mecbotamab vedotin (Mec-V, BA3011, Conditionally Active Biologic CAB-AXL-ADC) is designed to reduce off-tumor toxicity and improve pharmacokinetics by conditionally binding to AXL under low-pH conditions (pH

Fields of Study & Subjects

Phagocytosis and Immune Regulation Cancer Research and Treatments Sarcoma Diagnosis and Treatment

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
16_suppl
Pages
11511–11511
Publication date
27 May 2026
Language
EN